Body
A rare syndrome has been observed in people following vaccination against Covid-19. This involves thrombosis at unusual sites in the body, associated with a low thrombocyte (blood platelet) count and a clotting disorder. In medical jargon, this syndrome is referred to as VITT (vaccine-induced thrombotic thrombocytopenia). Doctors at the Department of Medicine I of MedUni Vienna and Vienna General Hospital (Division of Hematology and Hemastaseology) have now successfully treated an acute instance of this syndrome.
Patients with both diabetes and heart failure who were treated with sotagliflozin, a novel investigational drug for diabetes, for a median of nine to 16 months experienced reductions of 22% to 43% in the risk of death or worsening heart failure compared with similar patients who were treated with a placebo.
A program designed to improve hospital care for patients with heart failure, the leading cause of hospitalization among adults over age 65, did not bring additional benefits beyond existing hospital quality improvement programs in a randomized controlled trial presented at the American College of Cardiology's 70th Annual Scientific Session.
Heart failure is a condition in which the heart becomes too weak or too stiff to pump blood effectively to the rest of the body. It causes symptoms such as swelling and fluid retention, shortness of breath and coughing.
As Covid-19 spread around the world, stock markets in individual countries took a major hit - yet stock markets in China where the disease first struck avoided significant falls - researchers at Lero, the Science Foundation Ireland Research Centre for Software found.
Top experts from Brigham and Women's Hospital presented outcomes from some of the most-anticipated clinical trials in cardiology at the virtual American College of Cardiology's 70th Annual Scientific Session. In four Late-Breaking Clinical Trial presentations, Brigham cardiologists shared their latest findings on strategies to prevent future cardiovascular events in at-risk patient populations, results of a randomized clinical trial of a statin drug among patients critically ill with COVID-19, and more.
Sophia Antipolis, 17 May 2021: Women with mildly elevated blood pressure in their early 40s have a two-fold risk of acute coronary syndromes in their 50s compared to their counterparts with normal blood pressure. That's the finding of a study published on World Hypertension Day in the European Journal of Preventive Cardiology, a journal of the European Society of Cardiology (ESC).1
A unique commission that today issued major new recommendations aimed at fully understanding and reducing the global burden of heart disease in women was led by Roxana Mehran, MD, Professor of Medicine, and Population Health Science and Policy, and Director of Interventional Cardiovascular Research and Clinical Trials at the Icahn School of Medicine at Mount Sinai.
The Lancet women and cardiovascular disease Commission outlines 10 ambitious recommendations to improve health outcomes for millions of women around the world and achieve the global targets set.
ATS 2021, New York, NY - By removing "race correction" from the interpretation of pulmonary function test (PFT) results, Black individuals were shown to have a significantly higher prevalence and severity of lung disease, according to research presented at the ATS 2021 International Conference.
NEW YORK, NY (May 16, 2021)--Brief pulses of ultrasound delivered to nerves near the kidney produced a clinically meaningful drop in blood pressure in people whose hypertension did not respond to a triple cocktail of medications, reports a new study led by researchers at Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian.
An innovative cardiac rehabilitation intervention started earlier and more custom-tailored to the individual improved physical function, frailty, quality-of-life, and depression in hospitalized heart failure patients, compared to traditional rehabilitation programs. Supported by the National Institute on Aging (NIA), part of the National institutes of Health, these new study results were published May 16 in the New England Journal of Medicine and also presented at the American College of Cardiology's 70th Annual Scientific Session.
Research led by scientists at Children's Cancer Institute and published this week in the international journal, Clinical Cancer Research, has found a combination of therapies that appears to be highly effective against high-risk neuroblastoma and other forms of aggressive childhood cancer.
What The Study Did: Researchers analyzed changes in filled prescriptions for naloxone (medication to reverse opioid overdoses) during the COVID-19 pandemic in the United States and compared them with changes in opioid prescriptions and overall prescriptions.
Authors: Ashley L. O'Donoghue, Ph.D., of the Beth Israel Deaconess Medical Center in Boston, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
What The Study Did: Associations of staffing and testing interventions with COVID-19 transmission in nursing homes are examined in this decision analytical modeling study.
Authors: Rebecca Kahn, Ph.D., of the Harvard T.H. Chan School of Public Health in Boston, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2021.10071)
People with a high polygenic risk score for colorectal cancer could benefit more at preventing the disease by leading healthy lifestyles than those at lower genetic risk, according to a study by Vanderbilt researchers published in the April issue of The American Journal of Clinical Nutrition.